Head-to-head evidence
Olanzapine (TV-44749) vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (TV-44749)
Developed by Teva Pharmaceutical Industries
NCT05693935 · Phase 3 · completed
The 675-participant study was randomized, quadruple-blind, and placebo-controlled, with approximately 165 to 169 participants per blinded treatment group. Its primary clinical endpoint, change in PANSS total score at week 8, was significantly better with each TV-44749 dose than with placebo (all adjusted p<0.0001), supporting a strong evidence rating for the blinded efficacy comparison.
Paliperidone (Invega)
Marketed by Johnson & Johnson
NCT00077714 · Phase 3 · completed
The study was randomized and double-blind, but it enrolled only 12 participants and the registry does not clearly identify a comparator arm. Its primary endpoint was a clinical symptom measure (PANSS), but whether it was met cannot be determined because results are not posted.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (TV-44749)'s landscape · Paliperidone (Invega)'s landscape